Diagnostics

Portfolio

Process Innovation

1. Finding business ideas

Inven2 works actively with discovering ideas at Oslo University Hospital and the University of Oslo. Our goal is that all employees at these institutions shall have their personal Inven2 contact.

2. Evaluation

When you send your idea to Inven2 it will be carefully assessed on the basis of technological requirements, considered whether the intellectual rights can be protected and whether it has commercial potential. If your idea passes this test a project is created and resources are assigned. The assessment will be done in collaboration with you. You will receive our evaluation within 2 months.

3. Market Analysis

When the idea has qualified as a project, we develop a commercial strategy in the form of a business concept where we uncover the market need and clarify the necessary steps to bring the idea from technology to a new product. This work is done in close cooperation with industry to identify the critical factors for successful commercialization. Based on the commercial strategy, we develop a strategy for securing intellectual rights.

4. Verification

Verification of technology and markets is necessary to bring the idea from technology to product. This is a very resource-intensive phase that requires public funding. The Norwegian Research Councils FORNY program is a very important contributor for realization of ideas in this phase.

5. Realization

Our goal is to license your idea to existing industry or create a new business based on the idea. We develop a business plan or a detailed strategy for the acquisition of capital or licensing of the idea. As a significant incentive the inventor of the idea will receive 1 / 3 of net licensing revenues.

6. Corporate Development

Inven2 will follow the new start-up company or licensing partner closely. Our goal is for companies to be as independent as possible and to have the financial strength to develop further according to the business plan. We constantly seek partners for our start-up companies in order to secure funding and commercial success.

Success stories

Larsen and Bruland’s third cancer company will treat cancer that has spread to the abdominal cavity. They have previously enjoyed success with Algeta, which was sold for NOK 17.6 billion to Bayer, and Nordic Nanovector, which has a market value of almost NOK 5 billion.